Recently, CheckMate-648 and ESCORT-1st confirmed a 3-month survival benefit in patients with ESCC from the chemo-IO combination (14,15) (Table  1; Supplementary Table 1, available online), and actually there was a more than 6-month OS gain when nivolumab was administered with chemotherapy in the PD-L1 ≥ 1 population (mOS = 15.4 vs 9.1 months; HR = 0.54, 95% CI = 0.37 to 0.80, P < .0001) (15). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.